Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Mi Sun | - |
dc.contributor.author | Dong, Seung Myung | - |
dc.contributor.author | Kim, Boh-Ram | - |
dc.contributor.author | Seo, Seung Hee | - |
dc.contributor.author | Kang, Sokbom | - |
dc.contributor.author | Lee, Eun-Ju | - |
dc.contributor.author | Lee, Seung-Hoon | - |
dc.contributor.author | Rho, Seung Bae | - |
dc.date.available | 2019-03-08T21:40:01Z | - |
dc.date.issued | 2014-07 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12045 | - |
dc.description.abstract | Thioridazine, a member of the phenothiazine family, is a powerful anti-anxiety and anti-psychotic drug. It can also suppress the growth of several types of tumor in vitro. In the current study, we evaluated the direct anti-tumor and anti-angiogenic effects of thioridazine in vivo. The injection of thioridazine into human ovarian tumor xenografts in nude mice significantly inhibited tumor growth by similar to fivefold, and also decreased tumor vascularity. In addition, thioridazine inhibited the phosphorylation of the signaling molecules downstream of phosphatidylinositol-3'-kinase (PI3K), including Akt, phosphoinositide-dependent protein kinase 1 (PDK1), and mammalian target of rapamycin (mTOR), during ovarian tumor progression via vascular endothelial growth factor receptor 2 (VEGFR-2). These results provide convincing evidence that thioridazine regulates endothelial cell function and subsequent angiogenesis by inhibiting VEGFR-2/PI3K/mTOR signal transduction. Collectively, these results strongly suggest that thioridazine might be a novel anti-tumor and anti-angiogenic agent for use in ovarian cancer. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.title | Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts | - |
dc.type | Article | - |
dc.identifier.doi | 10.18632/oncotarget.2063 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.5, no.13, pp 4929 - 4934 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000347918500027 | - |
dc.identifier.scopusid | 2-s2.0-84904962883 | - |
dc.citation.endPage | 4934 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 4929 | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 5 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | thioridazine | - |
dc.subject.keywordAuthor | anti-tumor effect | - |
dc.subject.keywordAuthor | anti-angiogenic activity | - |
dc.subject.keywordAuthor | mTOR signaling | - |
dc.subject.keywordAuthor | xenograft model | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | VEGFR-1 | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | MTOR | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.